Phase 1 Clinical Trial of Sm-TSP-2 Schistosomiasis Vaccine Begins

WASHINGTON, D.C. — June 3, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today released an update on a Phase 1 clinical trial of its vaccine candidate to prevent intestinal schistosomiasis, Sm-TSP-2/Alhydrogel®. Schistosomiasis is one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poorest communities. The Sabin PDP is based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine (BCM) in Houston, Texas.

From April 30 to May 3, the Coalition against Typhoid (CaT) Secretariat, with coordination and support from PT Bio Farma, convened nearly 250 participants from 36 countries for the 9th International Conference on Typhoid and Invasive Non-Typhoidal Salmonella (iNTS) Disease.

Image: Child undergoing scan at Dengue High Dependency Unit Negombo General Hospital